DNMT3B -149 C>T and -579 G>T Polymorphisms and Risk of Gastric and Colorectal Cancer: a Meta-analysis

  • Khoram-Abadi, Khadijeh Mirzaee (Department of Anatomy, Internationl Campus, Shahid Sadoughi University of Medical Sciences) ;
  • Forat-Yazdi, Mohammad (Department of Internal Medicine, Internationl Campus, Shahid Sadoughi University of Medical Sciences) ;
  • Kheirandish, Shahnaz (Department of Internal Medicine, Internationl Campus, Shahid Sadoughi University of Medical Sciences) ;
  • Saeidi, Nasim (Department of Internal Medicine, Internationl Campus, Shahid Sadoughi University of Medical Sciences) ;
  • Zarezade, Zeinab (Department of Internal Medicine, Internationl Campus, Shahid Sadoughi University of Medical Sciences) ;
  • Mehrabi, Nahid (Department of Biology, Science Faculty, University of Yazd) ;
  • Neamatzadeh, Hossein (Department of Medical Genetics, Internationl Campus, Shahid Sadoughi University of Medical Sciences)
  • Published : 2016.06.01

Abstract

Background: Numerous studies have investigated associations of DNA methyltransferase (DNMT) -149 C>T and -579 G>T polymorphisms with gastric cancer (GC) and colorectal cancer (CRC) susceptibility; however, the findings are inconsistent prompting the present meta-analysis. Materials and Methods: Related studies were identified from PubMed, Google scholar, and SID until 10 October 2015. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. Results: Eleven studies were included based on the search criteria for CRC and GC related to the DNMT3B 149 C>T (3,353 cases and 4,936 controls) and DNMT3B 579 G>T (1,387 cases and 2,064 controls) polymorphisms. There was no significant association overall between DNMT3B -149 and 579 polymorphisms and the risk of cancer. In the stratified analysis by cancer type, DNMT3B 579G>T polymorphism was associated with the risk of CRC and GC. While the DNMT3B -149C/T polymorphism was related with a significantly increased risk of CRC in two tested models, dominant (GG+GT vs. TT: OR 0.51, 95 % CI 0.38-0.69; P = 0.00, Pheterogeneity=0.69, $I^2=0%$) and heterozygote (GT vs. TT: OR 0.50, 95 % CI 0.37-0.69; P=0.00, Pheterogeneity=0.41, $I^2=0%$), no evidence of any association with GC risk was observed as in the pooled analyses. Conclusions: More studies are needed to assess associations of DNMT3B -149C/T and DNMT3B 579G>T polymorphisms with cancer in different ethnicities with large population sizes to generate comprehensive conclusions.

Keywords

DNA methyltransferases;CRC;gastric cancer;polymorphism

References

  1. Attia J, Thakkinstian A, D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol, 56, 297-303. https://doi.org/10.1016/S0895-4356(03)00011-8
  2. Aung PP, Matsumura S, Kuraoka K, et al (2005). No evidence of correlation between the single nucleotide polymorphism of DNMT3B promoter and gastric cancer risk in a Japanese population. Oncol Rep, 14, 1151-4.
  3. Bao Q, He B, Pan Y, et al (2011). Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer. Int J Colorectal Dis, 9, 1107-12.
  4. Fan H, Zhang F, Hu J, et al (2008). Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J Exp Clin Cancer Res, 27, 24. https://doi.org/10.1186/1756-9966-27-24
  5. He M, Fan J, Jiang R, et al (2013). Expression of DNMTs and genomic DNA methylation in gastric signet ring cell carcinoma. Mol Med Rep, 8, 942-8. https://doi.org/10.3892/mmr.2013.1566
  6. Hermann A, Gowher H, Jeltsch A (2004). Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci, 61, 2571-87. https://doi.org/10.1007/s00018-004-4201-1
  7. Hu J, Fan H, Liu D, Zhang S, Zhang F, Xu H (2010) DNMT3B promoter polymorphism and risk of gastric cancer. Dig Dis Sci, 55, 1011-6. https://doi.org/10.1007/s10620-009-0831-3
  8. Iacopetta B, Heyworth J, Girschik J, et al (2009). The MTHFR C677T and ${\Delta}$DNMT3B C -149T polymorphisms confer different risks for right and left-sided colorectal cancer. Int J Cancer, 125, 84-90. https://doi.org/10.1002/ijc.24324
  9. Jones JS, Amos CI, Pande M, et al (2006). DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev, 15, 886-91. https://doi.org/10.1158/1055-9965.EPI-05-0644
  10. Jin B, Robertson KD (2013). DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol, 754, 3-29.
  11. Karpinski P, Myszka A, Ramsey D, et al (2010). Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. Cancer Epidemiol, 34, 338-44. https://doi.org/10.1016/j.canep.2010.03.002
  12. Karpinski P, Myszka A, Ramsey D, et al (2009). Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG Island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev, 18, 3086-96. https://doi.org/10.1158/1055-9965.EPI-09-0289
  13. Naghibalhossaini F, Mokarram P, Khalili E, et al (2015). DNMT3b -149C/T promoter variants and methylation of colorectal cancer-associated genes. Cancer Biomark, 15, 227-33. https://doi.org/10.3233/CBM-150463
  14. Pavlopoulou A, Kossida S (2010). Cytosine methyltransferases as tumor markers. Curr Genomics, 11, 568-77. https://doi.org/10.2174/138920210793360916
  15. Reeves D, Mossman CJ, Meldrum G, et al (2008). The -149C>T SNP within the ${\Delta}$DNMT3B gene, is not associated with early disease onset in hereditary non-polyposis colorectal cancer. Cancer Lett, 265, 39-44. https://doi.org/10.1016/j.canlet.2008.02.005
  16. Vizoso M, Puig M, Carmona FJ, et al (2015). Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis, 36, 1453-63.
  17. Wang C, Jia Z, Cao D, et al (2015). Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric Cancer. PLoS One, 10, 134059.
  18. Wang YM, Wang R, Wen DG, et al (2005). Single nucleotide polymorphism in DNA methyltransferase 3B promoter and its association with gastric cardiac adenocarcinoma in North China. World J Gastroenterol, 11, 3623-7. https://doi.org/10.3748/wjg.v11.i23.3623
  19. Xia Z, Duan F, Jing C, et al (2015). Quantitative assessment of the association between DNMT3B-579G>T polymorphism and cancer risk. Cancer Biomark, 15, 707-16. https://doi.org/10.3233/CBM-150512
  20. Zhu J, Du S, Zhang J, et al (2015). Polymorphism of DNA methyltransferase 3B -149C/T and cancer risk: a metaanalysis. Med Oncol, 32, 399. https://doi.org/10.1007/s12032-014-0399-4
  21. Zhang Y, Xu H, Shen Y, et al (2015). Association of DNMT3B -283 T > C and -579 G > T polymorphisms with decreased cancer risk: evidence from a meta-analysis. Int J Clin Exp Med, 8, 13028-38.